NEW YORK (GenomeWeb News) - Siemens Healthcare and Laboratory Corporation of America have agreed to "discuss future possibilities" to co-develop clinical diagnostic tests, the companies said today.
The non-exclusive agreement encompasses the areas of metabolic syndrome, oncology, diabetes, and companion diagnostics that are "designed to identify the suitability between patients and a particular drug therapy," the partners said.
"This agreement establishes a framework that gives both companies the opportunity to offer new diagnostic tests to laboratories, physicians and their patients more quickly and effectively than either could do alone," said Dave Hickey, senior vice president of strategic planning and business development at Siemens Healthcare Diagnostics, in a statement.
Myla Lai-Goldman, executive vice president, chief scientific officer, and medical director for LabCorp, said that the firm is particularly interested in the impact of the collaboration on the reference lab’s companion diagnostics efforts.
"Alliances, such as this between developers and providers of new tests, are critical in translating emerging biomarkers from research into clinical practice," she said.